Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Indeed, small studies have demonstrated that SGLT2 inhibitors can be utilized safely and efficaciously in patients with lupus nephritis, though with fewer studies on GLP1-RA
CA residents: Loans by Affirm Loan Services, LLC are made or arranged pursuant to California Finance Lender license 60DBO-111681
Tirzepatide is administered as a once-weekly subcutaneous injection, with a recommended starting dose of 2.5 mg once weekly for 4 weeks, then increasing by 2.5 mg every 4 weeks until the target dose (up to 15 mg) is reached
Sample Size Calculation The sample size was calculated based on detecting a clinically meaningful difference in mean weight loss between the IGB-only group and the IGB + Semaglutide at the 6-month follow-up
